Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Aeola Health Solutions United States

An investment group transforming

the world of healthcare one sector at a time.

We consolidate CROs and medical labs.
Website:
aeolahealthsolutions.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Find potential investors and strategic partners. Our strategy allows investors to triple their investment.
Headquartner in China
No
Biotech/Pharma Category
Mr. Michael Ezem
Aeola Health Solutions 
Functionality
Investment

Aventurine Capital Management, LLC United States

We bring foundational science and commercial viability together for social and market impact.

We provide a human innovation ecosystem offering commercially focused support for inventors.

DEEP TECH FUNDING REINVENTED WITH SCIENCE, FOR SCIENCE

6 practice areas: AI, Robotics, Life Science, Quantum Computing, Energy, Secure Platforms & Networks
Website:
www.aventurine.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Strategic collaboration
Headquartner in China
No
Biotech/Pharma Category
Mr. Avery Lu
Investment Research Lead 
Functionality
Investment

Capital Family Office United States

Investor
Website:
na
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
JV's; Licensing in/out
Headquartner in China
No
Biotech/Pharma Category
Steven Olasky
Pricipal 
Functionality
Investment

Cytovance Biologics United States

Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.
Website:
www.cytovance.com
Company Size (Fulltime employees)
201-500
Year of foundation
2005
Partnering Objectives
Please specify your partnering goal
TBD
Headquartner in China
No
Biotech/Pharma Category
Mr. Matt Delaney
VP of Business Development and Marketing 
Functionality
Business Development

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Website:
www.dao-tun.ch
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
looking for clients and partners who have interest to enter Chinese market for fundraising, licensing, partnering etc.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality
Management

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Website:
http://www.gcvlife.com/
Company Size (Fulltime employees)
11-50
Year of foundation
2008
Partnering Objectives
Please specify your partnering goal
Looking for organizations with deep relationship in the Chinese markets, who can act as our representative in the region to license select products to marketing companies in the Chinese market.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Chirag Jain
Analyst 
Functionality
Business Development

GIG China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ￥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
51-200
Partnering Objectives
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Yes
Biotech/Pharma Category
Medtech Development Stage
Denise Chen
Partner 
Functionality
Investment

Hetero Biopharma India

We are into Mabs - Biosimilars
Website:
WWW.heterobiopharma.com
Company Size (Fulltime employees)
501-1000
Partnering Objectives
Please specify your partnering goal
We are in need of ample amount of fund to proceed with clinical trials for one of our projects ...and we are looking for partners for help us achieve this goal
Headquartner in China
No
Biotech/Pharma Category
Mr. Mani Arjun
Research associate 
Functionality
Research and Development

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Website:
http://www.hrs.com.cn/company_summary.html
Company Size (Fulltime employees)
5000+
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality
Business Development

Mesa Verde Venture Partners United States

Life Sciences venture capital fund with three funds under management.
Website:
www.mesaverdevp.com
Company Size (Fulltime employees)
1-10
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Meeting investors and potential companies
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
not applicable|||
Mr. Randy Berholtz
Senior Advisor 
Functionality
Management